Data investigation

What Changed in the Teenagers' Bloodwork

A STEP TEENS analysis found insulin resistance down 35%, liver enzymes down 18%, and lipids improved in 12-to-17-year-olds. All of it is bloodwork, and the outcomes it stands in for are decades away.

By Nora Bissett · Pricing Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed
7 min read·1 citation

The STEP TEENS trial established that semaglutide reduces BMI in adolescents. This follow-up analysis asked what else moved, and nearly everything measurable did. Insulin resistance fell 35%, liver enzymes fell 18%, and cholesterol and triglycerides improved.[1] All of it is bloodwork. In a fourteen-year-old, the outcomes those markers stand in for are four decades away. For the weight results themselves and what a parent should ask about them, see GLP-1 drugs in teenagers.

What was found

The analysis covered 193 participants aged 12 to under 18 who had obesity but not type 2 diabetes. Over 68 weeks, 129 took weekly semaglutide 2.4 mg and 64 took placebo.

Change from baseline at week 68, semaglutide 2.4 mg against placebo.[1]
MeasureSemaglutidePlaceboP
Fasting serum insulin−33.6%−10.1%0.0012
HOMA-IR (insulin resistance)−35.0%−5.3%0.0002
ALT (liver enzyme)−17.9%−3.3%0.0232
HbA1c——<0.0001
Fasting plasma glucose——0.0181
Triglycerides——<0.0001
LDL cholesterol——0.0105
Total cholesterol——<0.0001
Waist-to-height ratio——<0.0001

The liver result is the one that is not decades away

Most of that table describes risk accumulating toward events in middle age. ALT is different. Fatty liver disease is now the most common chronic liver condition in children, it is driven by exactly this metabolic picture, and elevated ALT is how it is usually first noticed.

So the 17.9% fall, against 3.3% on placebo, is not a stand-in for a distant outcome. It measures something a substantial share of these teenagers plausibly already had, and it is moving in the right direction now. Of everything in the analysis, this finding has the shortest distance between the number and a real condition.

Why the rest needs holding lightly

These are surrogate markers, and in adolescents the surrogate is all there will ever be. In an adult trial you can sometimes count heart attacks within the study. In a twelve-year-old, the events these markers predict fall decades after any trial anyone will run. That makes the surrogate unavoidable, and that is a reason for caution, not a reason to promote it to an outcome.

Markers moving the right way while patients do worse is a problem that has bitten cardiology more than once; it is set out in a biomarker is not an outcome. Nothing here suggests that is happening. But improved adolescent bloodwork is a promising sign, not a demonstrated reduction in lifetime disease.

Two structural caveats belong with the numbers. This is a secondary analysis of a trial designed and powered to measure BMI, so these endpoints are being asked of data collected for another purpose. And the randomization ran two-to-one, leaving only 64 people on placebo, which is a small comparison group for a nine-row table.

One comparison in the paper that is not randomized

The analysis also reports that participants whose BMI fell by 20% or more had greater improvements than those whose BMI fell less. That reads like a dose-response relationship, which would strengthen the case considerably. It is not one.

Everyone in that comparison received the drug. Splitting treated participants by how well they responded compares responders with non-responders, two groups that were never randomized against each other. Whatever makes someone lose more weight on semaglutide may independently improve their insulin sensitivity. The comparison cannot separate the two, and no analysis of it can.

It is a reasonable thing to report and an easy thing to over-read. A real dose-response analysis would compare randomly assigned doses, not self-selected outcomes.

What is still unknown

  • Long-term safety in a growing body. Sixty-eight weeks is the evidence base. Puberty, bone accrual and final adult height are not addressed by it.
  • What happens on stopping. No one plans to take a medication indefinitely through adolescence without knowing that.
  • Whether any of these markers translate into fewer events, which no trial in this age group can answer.
  • Effects on eating behavior and body image during adolescence, which this analysis did not measure.

None of this argues against the drug in adolescents. It argues for describing what is known without making it sound bigger than it is.

Frequently Asked Questions

Over 68 weeks it reduced fasting insulin by 33.6% against 10.1% on placebo, insulin resistance by 35.0% against 5.3%, and the liver enzyme ALT by 17.9% against 3.3%, with improvements in HbA1c, fasting glucose, triglycerides, LDL and total cholesterol.
Arguably the ALT reduction. Fatty liver disease is the most common chronic liver condition in children and elevated ALT is how it is usually detected, so that number maps to something these teenagers may already have rather than to a risk decades away.
Unknown, and not answerable by any trial in this age group. These are surrogate markers, and the events they predict fall decades after any study anyone will run.
No. Everyone in that comparison received the drug, so it compares people who responded well with people who did not, and those groups were never randomized against each other. Whatever causes a larger response may independently improve these markers.
No. The evidence base here is 68 weeks. Effects across puberty, on bone accrual and on final adult height are not addressed.

References

  1. 1.Arslanian S, Gies I, Goldman B, et al. Effect of Semaglutide on Insulin Sensitivity and Cardiometabolic Risk Factors in Adolescents With Obesity: The STEP TEENS Study Diabetes Care. 2026. PMID: 41296499.

Tirzepatide in Ten- to Seventeen-Year-Olds

Youth-onset type 2 diabetes moves faster and responds worse than the adult disease. In 99 children aged 10 to 17, tirzepatide cut HbA1c by 2.23% while the placebo group's blood sugar rose.

6 min read

The Old Cheap Drug Keeps Winning

A network meta-analysis of 41 pediatric trials found semaglutide producing the largest BMI reduction, and concluded an older, cheaper combination may be the better option.

7 min read

GLP-1 Drugs in Teenagers: What 18 Trials Show

Eighteen randomized trials in 1,402 children and adolescents with obesity, prediabetes or type 2 diabetes found improvements across every metabolic measure. Weight fell 3.02 kg more than on placebo, and the median treatment duration across all of them was half a year.

6 min read

A Trial About the Measuring Instrument

SAMARA will be reported as showing semaglutide improves fatty liver disease. It was built to ask whether non-invasive tests can replace a biopsy, and the drug was the tool used to answer it.

7 min read

The Biggest Number Is the Weakest

A prespecified SELECT analysis reports cardiovascular reductions of 26%, 21% and 34% across three definitions of liver fibrosis risk. The 34% is the only one that was not statistically significant.

7 min read

The Line Is Drawn by Surgery

A meta-regression found study arms with greater average weight loss had higher rates of fatty liver disease resolving. The authors say plainly it cannot establish cause, and a handful of surgical arms are pulling the line.

6 min read

Where to get GLP-1 online, safely: sellers our editors have checked

These are telehealth sellers our editors have checked. For each one we hold a price, the form the drug comes in, and the states it reaches.

No insurance needed · vetted by our editors

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

7.9

Luvo Health

Moving between compounded and brand without changing seller

7.2

Oak

A choice of compounded injections, oral semaglutide and brand-name GLP-1s from one cash-pay checkout

8.7

Eden

Coverage in all 50 states, which most sellers will not confirm

About this analysis

GLP Watchdog publishes independently. Each seller in our dataset is checked against that seller's own website, and the dataset is updated continuously. Read our full methodology →